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Genome-wide co-occupancy of AML1-ETO and
N-CoR defines the t(8;21) AML signature in
leukemic cells
Daniel J Trombly2†, Troy W Whitfield2,3†, Srivatsan Padmanabhan2, Jonathan AR Gordon1,2, Jane B Lian1,2,
Andre J van Wijnen2,4, Sayyed K Zaidi1,2, Janet L Stein1,2 and Gary S Stein1,2*
Abstract
Background: Many leukemias result from chromosomal rearrangements. The t(8;21) chromosomal translocation
produces AML1-ETO, an oncogenic fusion protein that compromises the function of AML1, a transcription factor
critical for myeloid cell differentiation. Because of the pressing need for new therapies in the treatment of acute
myleoid leukemia, we investigated the genome-wide occupancy of AML1-ETO in leukemic cells to discover novel
regulatory mechanisms involving AML-ETO bound genes.
Results: We report the co-localization of AML1-ETO with the N-CoR co-repressor to be primarily on genomic regions
distal to transcriptional start sites (TSSs). These regions exhibit over-representation of the motif for PU.1, a key
hematopoietic regulator and member of the ETS family of transcription factors. A significant discovery of our
study is that genes co-occupied by AML1-ETO and N-CoR (e.g., TYROBP and LAPTM5) are associated with the
leukemic phenotype, as determined by analyses of gene ontology and by the observation that these genes are
predominantly up-regulated upon AML1-ETO depletion. In contrast, the AML1-ETO/p300 gene network is less
responsive to AML1-ETO depletion and less associated with the differentiation block characteristic of leukemic
cells. Furthermore, a substantial fraction of AML1-ETO/p300 co-localization occurs near TSSs in promoter regions associated
with transcriptionally active loci.
Conclusions:Our findings establish a novel and dominant t(8;21) AML leukemia signature characterized by occupancy of
AML1-ETO/N-CoR at promoter-distal genomic regions enriched in motifs for myeloid differentiation factors, thus
providing mechanistic insight into the leukemic phenotype.
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Background
Runx1, also known as AML1, is a frequent target of
chromosomal translocations in myeloid progenitor cells
[1]. The t(8;21) chromosomal translocation accounts for
approximately 15% of acute myeloid leukemia (AML)
cases and produces the AML1-ETO fusion protein [2].
AML1-ETO is comprised of the AML1 N-terminus,
containing the conserved DNA-binding runt homology
domain (RHD), fused with almost the entire eight
twenty-one (ETO) protein [3]. ETO contains four con-
served nervy homology regions (NHR) that bind differ-
ent transcriptional repressive complexes including
histone deacetylases and the silencing mediator of retin-
oic acid and thyroid hormone receptor (SMRT) com-
plex [4]. All four NHRs are retained in AML1-ETO, and
early reports demonstrated that the fusion protein
represses the transcription of AML1 target genes im-
portant for myeloid differentiation [5]. This repression
is mediated, in part, by interactions between AML1-
ETO and the nuclear co-repressor protein (N-CoR)
[6,7]. Recruitment of histone deacetylases (HDACs) by
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AML1-ETO and N-CoR leads to a loss of histone modi-
fications associated with transcriptional activation (e.g.,
H3K9ac), whereas blockade of HDAC activity results in
partial differentiation of leukemic cells [8-10]. In
addition, the acquisition of repressive histone modifica-
tion marks, including H3K27me3, is believed to serve as
an epigenetic mechanism for AML1-ETO mediated
gene repression [11,12].
The repressive activity of AML1-ETO does not repre-
sent its full range of functions. The fusion protein has
also been shown to activate genes [13-15], and a mechan-
ism for this transcriptional activation involving AML1-
ETO and p300 interactions has recently been described
[16]. AML1-ETO affects the function of microRNAs
(miRs [15,17]), DNA repair proteins [18], and growth
factors in myeloid progenitor cells [19]. The fusion pro-
tein also plays a role in epigenetic-controlled cell growth
via interactions with rDNA repeats [20]. In addition to
regulating gene expression directly, AML1-ETO inter-
feres with the transcriptional activities of molecules
important for myeloid cell differentiation via protein-
protein interactions and acts as an organizer of cofactor
exchange [21-23]. Taken together, these studies showed
that AML1-ETO acts as a transcriptional regulator and
modifies transcription factor activity via differential co-
factor recruitment, properties that maintain the onco-
genic character of t(8;21) leukemic cells.
Recently, genome-wide binding of AML1-ETO, AML1,
and p300 has been determined in leukemic cells [24-26].
These studies have shown the following: global AML1
and AML1-ETO binding sites largely overlap [24], ETS-
family proteins recruit AML1-ETO [27], and that PU.1, a
master regulator of myeloid cell differentiation, is part of
the t(8;21) core transcriptional network. AML1-ETO and
the coactivator p300 co-occupy hypoacetylated genomic
loci in leukemic cells [26], yet the relevance of this
phenomenon to t(8;21) leukemia is not well-understood.
In addtion, global interactions between AML1-ETO and
N-CoR have not been studied. To clarify these issues, we
employed chromatin immunoprecipitation with high-
throughput sequencing (ChIP-seq [28]) and determined
genome-wide sites of enrichment for AML1, AML1-
ETO, N-CoR, and p300 in Kasumi-1 cells, a model sys-
tem for t(8;21) leukemia [29]. ChIP-seq libraries for
histone modifications associated with transcriptional
activation (H3K4me3) and repression (H3K27me3) were
also generated to assess whether epigenetic mechanisms
account for the differentiation arrest phenotype in
Kasumi-1 cells.
From our genome-wide analysis of AML1/AML1-ETO
occupancy, we have identified and described a phenotypic-
ally relevant subset of putative regulatory sequences.
These sequences are characterized by abundant N-CoR
co-occupancy, relative to other AML1/AML1-ETO-bound
sequences, and a significant enrichment in PU.1 motifs.
Moreover, using publicly available gene expression data
[24,30], we show by in silico analysis that genes associated
with the AML1-ETO/N-CoR co-occupancy signature
display significantly greater recovery of expression
upon reduction of AML1-ETO mRNA levels than do
other AML1-ETO-bound genes. AML1-ETO/N-CoR
co-occupied genomic loci tended to be distal from
transcriptional start sites (TSSs) and showed little en-
richment in the H3K4me3 histone modification. Finally,
gene ontology analysis of genomic regions associated
with AML1-ETO/N-CoR enrichment was more rele-
vant to the differentiation block exhibited by Kasumi-1
cells compared to those regions enriched in AML1-
ETO/p300. Thus, although AML1-ETO both represses
and activates genes at the single-gene level [31], our
genome-wide data show that AML1-ETO predominatly
acts as a repressor. Our studies provide a new understand-
ing of the global mechanisms that regulate the t(8;21)
leukemic phenotype.
Results
AML1-ETO associates preferentially with the co-repressor
N-CoR
ChIP-seq studies were performed to identify AML1 and
AML1-ETO binding regions globally in the Kasumi-1
cell genome. In addition, ChIP libraries for molecular indi-
cators of transcriptional activation (p300 and H3K4me3)
and transcriptional repression (N-CoR and H3K27me3)
were generated. Prior to library preparation, antibodies
were validated through western blot and ChIP-PCR exper-
iments (Additional file 1: Figure S1 and Additional file 2:
Figure S2). For example, a known AML1 binding region
within the Runx1P1 promoter [32] was significantly
enriched in AML1-ETO ChIP samples compared to IgG
control samples (Additional file 2: Figure S2A). This find-
ing was confirmed in our ChIP-seq data, as sequence tag
density showed strong AML1-ETO binding at the
Runx1P1 site and negligible binding at a negative control
Phox region (Figure 1A and B [33]). ChIP-seq data for
AML1 yielded a similar binding profile at the Runx1 pro-
moter (Figure 1A). An AML1 antibody that recognizes the
C-terminus of Runx1, and therefore does not pull down
AML1-ETO, was used in ChIP-seq library preparations.
Model-based analysis of ChIP-seq data (MACS [34])
was used to identify protein binding or enrichment
regions (peaks) for histone modifications, AML1-ETO
and associated co-regulators in the Kasumi-1 genome
(Additional file 3: Table S1). AML1-ETO was enriched at
genes that are known to be regulated by the fusion protein
[15,17,24,30], underscoring the quality of our ChIP-seq
data (Figure 1D and Additional file 4: Figure S3). Approxi-
mately 71% of AML1 peaks overlapped with those of
AML1-ETO (Figure 1C). This result was expected, as
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Figure 1 ChIP-seq analysis reveals global protein co-occupancy in Kasumi-1 cells. Tag density plots of normalized ChIP-seq data (combined
biological replicates) showing AML1 and AML1-ETO occupancy at Runx1P1 promoter (A) and negative control Phox (B) loci. Tags were normalized to 107
reads. Images were taken from the UCSC Genome Browser [63]. Asterisks indicate the positions of hRunx1P1 and hPhox regions tested in ChIP-PCR studies.
(C) Two-way and three-way Venn diagrams displaying co-occupancy and unique regions among AML1, AML1-ETO, N-CoR, and p300 libraries. All peaks
were generated by MACS using a p < 10−20 significance cutoff. Total peak numbers are displayed in parentheses. (D) Tag density plots
displaying enrichment of AML1-ETO and N-CoR at regions corresponding to known fusion protein target genes that are repressed in
Kasumi-1 cells.
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AML1-ETO retains the DNA-binding RHD found in
wild-type Runx1. Interestingly, 39% of AML1-ETO
peaks overlap those of N-CoR, whereas only 22% of
AML1-ETO peaks overlap those of p300 (Figure 1C).
A similar profile was observed when comparing the
co-occupancy of AML1 with the two co-regulators.
These findings are consistent with a correlation ana-
lysis of genomic occupancy from ChIP-seq measure-
ments (Additional file 5: Figure S4), which shows that
AML1-ETO and N-CoR signals are more correlated
with one another than either is with any of the other
assayed DNA-binding proteins, co-regulators or epige-
nomic modifications. A closer analysis of selected
genes that are related to the leukemia phenotype and
are deregulated upon siRNA-mediated AML1-ETO
depletion [24,30] (please see below) further confirms
an AML1-ETO/N-CoR dominant co-occupancy pat-
tern that may regulate the leukemic phenotype at the
genome-wide level (Figure 1D).
To evaluate the gene-sets that are likely to be per-
turbed by the binding of AML1-ETO and its cofactors,
we analyzed gene ontology terms. ChIP-seq peaks with
high statistical significance (p < 10−75) from each library
were analyzed using the Genomic Regions Enrichment
of AnnotationsTool (GREAT [35]). Enriched gene ontology
terms germane to molecular signatures of hematopoietic
and leukemic cells were similar among the AML1, AML1-
ETO and N-CoR datasets, but not that of p300 (Figure 2A
and B). Importantly, ontology terms derived from genomic
loci co-occupied by AML1-ETO and N-CoR were more
relevant to myeloid leukemia than those from regions ex-
clusively co-occupied by AML1-ETO and p300 (Additional
file 6: Figure S5). Ontology terms derived from regions
that display enrichments of AML1 with p300/N-CoR
and AML1-ETO with p300/N-CoR resemble those of the
fusion protein and N-CoR (Additional file 6: Figure S5).
Thus, AML1-ETO preferentially associates with N-CoR
compared to p300, and genes represented by these sites
reflect the leukemic phenotype of Kasumi-1 cells.
Transcription factors act in a combinatorial fashion to
regulate gene expression in hematopoietic progenitor
cells [36]. A similar situation likely occurs in Kasumi-1
cells, where interactions between AML1-ETO and dis-
tinct co-regulatory proteins at hematopoietic genes
Figure 2 AML1-ETO and N-CoR peaks relate to similar gene ontology terms and motifs discovered de novo. (A) Gene ontology was used to infer
biologically relevant pathways among ChIP-seq libraries using highly-ranked peaks (p < 10−75 from MACS). Shown are top-ranked gene ontology
terms within Biological Process (A) and Molecular Signatures Database Perturbation (B) [64]. Values on column plots represent –log10(binomial
p-value) computed using GREAT (version 2.0.2) [35] with the default association rules. Note: some ontology term names were shortened. (C)
HOMER de novo motif analysis [54] of AML1, AML1-ETO, N-CoR, and p300 libraries. Displayed are the top-ranked motifs for each library with
log(p-value) scores. Genomic loci occupied by AML1, the fusion protein and N-CoR were enriched in the Runx1 motif. Candidate transcription
factors that harbor these motifs (listed in the ranked list of motif results) are shown in parentheses.
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may be necessary to maintain differentiation arrest
[25,27]. In our genome-wide study, de novo motif dis-
covery revealed that Runx1 and ETS family motifs were
most commonly associated with AML1 and AML1-
ETO peaks (Figure 2C). ETS family motifs (please see
the Discussion section for candidate ETS motifs) were
also enriched in sites of N-CoR and p300 occupancy
(Figure 2C). Taken together, our data suggest that the
differentiation arrest in Kasumi-1 cells is caused by pu-
tative global AML1-ETO/ETS interactions and through
the repressive activity of the fusion protein on AML1-
mediated transcription.
PU.1 motifs are significantly associated with regions of
elevated AML1-ETO/N-CoR occupancy and low H3K4me3
enrichment
To characterize further the relationship between AML1,
AML1-ETO, the co-regulators p300 and N-CoR, and epi-
genetic signatures, the mean tag densities for these datasets
over regions (100 bp, centered on the summits of ChIP-seq
peaks) bound by AML1 and/or AML1-ETO were clustered
using k-means (Figure 3A). ChIP-seq enrichments for
H3K27me3 showed little correspondence with signals from
all other ChIP libraries (data not shown), yet this repressive
mark was associated with some AML1-ETO regulated
Figure 3 Classification of AML1/AML1-ETO genomic localization using co-factors. (A) Heatmap of significant (p < 10−20 from MACS) AML1/
AML1-ETO ChIP-seq peaks clustered using k-means (k = 3) with normalized mean (over summit +/- 50 bp regions) read densities for AML1,
AML1-ETO, N-CoR, p300 and the transcription initiation-associated histone modification H3K4me3. Following the color key, lowest read densities are
represented in dark blue, whereas highest signals are in tan. (B) Distribution of clustered AML1/AML1-ETO loci among five classes of genomic elements.
The y-axis represents the fraction of occupied loci among the each of the three clusters. (C) Profile of within-cluster averaged AML1, AML1-ETO, and
co-regulatory protein enrichments. (D) Plot showing the fraction of ChIP-seq peaks containing the PU.1 motif as a function of total peak numbers for
each cluster.
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genes including CXCR4 and HCK (Additional file 7:
Figure S6). At genomic regions where levels of AML1-
ETO and N-CoR enrichment were highest (Cluster I),
enrichment of the activating mark H3K4me3 was low
(Figure 3A and C). This anti-correlation is expected on
the basis that only a small fraction (6.3%) of the AML1/
AML1-ETO-bound loci from Cluster I are found at pro-
moters of the UCSC known genes (Figure 3B [37]), whereas
H3K4me3 enrichments are expected to be elevated at ac-
tively transcribed genes [38]. In contrast, Cluster II was
characterized by an inverse pattern, where occupancy of
AML1-ETO and N-CoR was lower (Figure 3C) but statisti-
cally significant (p < 10−20 for AML1-ETO and/or AML1
enrichment) and enrichment of H3K4me3 was high.
The mean occupancy of p300 was similar among the
three clusters (Figure 3C). Comparing our ChIP-seq data
with H3K9ac (another activation-associated histone modi-
fication) ChIP-seq data from Ptasinska et al [24], we ob-
served that enrichment of H3K9ac was inversely correlated
with our AML1-ETO and N-CoR occupancies (data not
shown). This inverse relationship between AML1-ETO/N-
CoR and activating histone marks reinforces the idea that
AML1-ETO acts as a transcriptional repressor at many loci
in Kasumi-1 cells.
We examined the distribution of AML1/AML1-ETO
bound loci from all three clusters among genomic ele-
ments (Figure 3B). AML1/AML1-ETO occupied regions
from Clusters I and III are gene-distal compared to those
of Cluster II. Yet, for each cluster the comparison with oc-
cupancy expected based upon AML1/AML1-ETO binding
with random sequences or sequences that match the
AML1 motif revealed differences. For example, for all
clusters AML1/AML1-ETO occupancy at promoters and
exons is higher than expected (Figure 3B). As noted above,
the occupancy reflected by Cluster II is much more
strongly associated with TSS-proximal elements than that
of Clusters I and III.
The sequences with the greatest AML1-ETO/N-CoR
co-occupancy (Cluster I) were compared with the
remaining sequences occupied by AML1/AML1-ETO
(Clusters II and III) using a discriminatory motif analysis
(see Methods). The ETS/PU.1 motif was over-represented
among the Cluster I sequences (p < 2.2 × 10−16 using a
Kolmogorov-Smirnov test). The resulting PU.1 motif
(Additional file 8: Figure S7) was scanned across all
AML1/AML1-ETO-occupied sequences using FIMO [39],
which demonstrated the relative enrichment of the PU.1
motif in distal, predominantly N-CoR-associated puta-
tive regulatory sequences (Cluster I) and depletion in
the proximal transcriptionally active sequences (Cluster
II) (Figure 3D). Thus, AML1-ETO/N-CoR interactions
likely perturb PU.1 function at multiple loci in the
Kasumi-1 cell genome, in turn contributing to the
leukemic phenotype of these cells.
The AML1-ETO/N-CoR signature is linked to AML1-ETO
target gene expression and leukemia
In order to relate the AML1-ETO/N-CoR co-occupancy
signature to phenotypic changes in gene expression, pu-
tative regulatory target genes were interrogated using
publicly available expression profiling data from AML1-
ETO mRNA knockdown experiments in Kasumi-1 cells
[30]. For a given gene, the t score is the estimated log
fold-change between conditions divided by its standard
error: we observe that P(t) is shifted significantly to
higher t for Cluster I compared to either Clusters II or
III (Figure 4A). This observation is further evident in the
volcano plot (Figure 4B), where genes associated with
Cluster I are over-represented (p < 2.5 × 10−5 comparing
with either Clusters II or III using Fisher’s exact test)
among genes with substantially altered expressiona.
Thus, relative to other AML1/AML1-ETO-bound genes,
those with the AML1-ETO/N-CoR signature (Cluster I)
were more transcriptionally repressed and therefore up-
regulated in AML1-ETO depleted Kasumi-1 cells. These
results were recapitulated using a second set of publicly
available expression profiling data from AML1-ETO
mRNA knockdown experiments in Kasumi-1 cells [24]
(see Figure 4C and D). In Figure 4D, genes associated
with Cluster I are over-represented (p < 2.5 × 10−4 com-
paring with either Clusters II or III using Fisher’s exact
test) among genes with substantially altered expression1.
Because we have observed a clear relationship between
AML1-ETO/N-CoR co-localization and siRNA-induced
abrogation of the leukemic phenotype in Kasumi-1 cells
(Figure 4A), it is worthwhile to compare the genes
linked with different patterns of AML1/AML1-ETO/co-
factor occupancy with those from gene ontology terms.
We find that the AML1-ETO/N-CoR signature is asso-
ciated with phenotypic terms including “myeloid cell
differentiation”, while Clusters II and III are more asso-
ciated with normal cellular function (Figure 5). Taken
together, gene expression and ontology data suggest
that the AML1-ETO/N-CoR signature establishes the
leukemic phenotype.
Discussion
Our ChIP-seq data demonstrate that AML1-ETO bind-
ing regions are more correlated with N-CoR in Kasumi-
1 cells than any other assayed proteins, including p300.
Using ChIP (re-ChIP) studies in Kasumi-1 cells, Ptasinska
et al determined that AML1-ETO preferentially recruits
the co-repressor HDAC2 (an N-CoR interacting partner)
instead of the co-activator p300 [25]. This genome-wide
study also revealed that AML1-ETO bound loci are chiefly
associated with transcriptional repression [25]. Thus, the
preferential association between AML1-ETO and N-CoR
in our study supports the finding that many AML1-ETO
regulated genes are repressed [24,25]. In SKNO-1 cells,
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another in vitro model system for t(8;21) leukemia,
AML1-ETO and p300 were also found to co-occupy gen-
omic regions [26], yet the relevance to the t(8;21) disease
phenotpye is unclear. Our integration of ChIP-seq data
with publicly available microarray data and gene ontology
analyses demonstrate that regions co-occupied by AML1-
ETO/N-CoR are more relevant to t(8;21) leukemia than
AML1-ETO/p300.
We found that genomic regions of AML1 occupancy
largely overlap AML1-ETO binding regions. A similar re-
sult has also been observed in ChIP-chip data of U937 cells
over-expressing AML1-ETO [40]. Ptasinska and colleagues
determined global DNA binding for AML1 and AML1-
ETO in Kasumi-1 cells [24,25]. Although we used different
AML1 and ETO antibodies for our ChIP experiments, there
is a very high correspondence (80%) of peaks between the
datasets (data not shown). Similar to reports of other tran-
scription factors in hematopoietic cell types [41,42],
AML1 and AML1-ETO largely occupy promoter-distal
sites (including introns) in the Kasumi-1 genome.
These results suggest that these distal sites serve as
platforms for AML1-ETO to regulate transcription via
long-range chromatin interactions. AML1 and fusion
protein occupancy at distal sites may be important for
maintaining chromatin structure and for scaffolding
protein-protein interactions. Approximately 20% of
AML1, fusion protein, and co-regulator peaks occupy
the same genomic regions. These ubiquitous sites may
reflect cell population effects and/or the different affin-
ities of p300 and N-CoR for AML1-ETO. Alternatively,
co-occupancy of opposing factors, N-CoR and p300,
may be an important mechanism for fine tuning chro-
matin at regulatory loci [43].
ChIP-seq data have been used to identify putative
protein partners via de novo motif discovery [41,44,45].
Each of our libraries was enriched in ETS factor motifs.
Figure 4 Genes associated with the AML-ETO/N-CoR signature have the greatest recovery upon AML1-ETO knockdown. (A) The cumulative
distribution of t scores, C tð Þ ¼
Z t
−∞
P sð Þds , comparing changes in gene expression for each of the clusters (Figure 3A) due to reduction in mRNA
levels of the AML1-ETO fusion protein [30] is shown. For a given gene, the t score is the estimated log fold-change between conditions divided
by its standard error: we observe that C(t) is shifted significantly (p < 4.6 × 10−10 using a t-test) to higher t for Cluster I compared to either Clusters II or III.
The inset shows the probability distributions, P(t), for each cluster. (B) Volcano plot of expression differences due to RNAi mediated knockdown of AML1-
ETO [30] showing genes from each of the clusters. The horizontal axis shows log2(fold-change), with vertical lines indicating cutoffs of 2-fold
in either direction. The upper panel displays the distributions of log2(fold-change) for each of the clusters, again with a significant shift (p < 4 × 10
−9
using a t-test) to higher fold-changes for Cluster I, relative to the other two clusters. (C) Distributions of t scores, as in (A) using expression profiling data
collected over several time-points in Kasumi-1 cells under knockdown of the AML1-ETO mRNA [24]. We observe that C(t) is shifted significantly
(p < 2.9 × 10−8 using a t-test) to higher t for Cluster I compared to either Clusters II or III. (D) Volcano plot of expression differences due to knockdown of
AML1-ETO [24] showing genes from each of the clusters. The upper panel displays the distributions of log2(fold-change) for each of the clusters, again with
a significant shift (p < 3.5 × 10−8 using a t-test) to higher fold-changes for Cluster I, relative to the other two clusters.
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A motif for one candidate ETS family member, FLI1,
was discovered within significant N-CoR and p300
peaks (Figure 2C). Our data corroborate a recent report
showing that FLI1 binds regions similar to AML1-ETO
and that the fusion protein is recruited to ETS factor
binding sites [27]. Although the AML1-ETO/N-CoR
signature appears to largely account for the leukemic
phenotype, Myb-p300 interactions may play a small
role in this disease phenotype. The Myb motif was
enriched in our p300 ChIP-seq dataset. Interestingly,
Pattabiraman et al demonstrated that interactions be-
tween C-Myb and p300 are important for initiating
acute myeloid leukemia [46]. Strikingly, ETS/PU.1 mo-
tifs were over-represented in Cluster I, implying that
AML1-ETO is potentially recruited by PU.1 and may be
necessary for maintaining differentiation arrest in
Kasumi-1 cells. This assertion, along with the specific
identity of PU.1 from among the highly similar ETS-
family motifs, was confirmed by Ptasinska et al, who
performed PU.1 ChIP-seq in Kasumi-1 cells and found a
high degree of overlap between PU.1 and AML1-ETO
associating regions [25]. Because AML1-ETO binds
DNA and also interacts with PU.1-bound to DNA [22],
the fraction of AML1-ETO peaks that represent directly
versus indirectly bound DNA is not known.
Previous reports have demonstrated that depletion of
AML1-ETO in Kasumi-1 cells resulted in global in-
creases in H3K9ac occupancy, an epigenetic mark for
transcriptional activation [24]. We examined genome-
wide enrichment sites for H3K4me3 and H3K27me3,
marks of activation and repression, respectively. AML1-
ETO mediated gene repression is believed to occur
through an epigenetic mechanism involving H3K27me3
[12]. Although this activity occurs at the LAT2 gene [47]
and only on a subset of our ChIP-seq peaks, the repres-
sion characterized by local alterations in H3K27me3 is
likely not the dominant mechanism in Kasumi-1 cells. In
contrast, H3K4me3 enrichments correlated well with
Figure 5 Ontologies for shared AML1-ETO and N-CoR genomic regions are relevant to leukemia. Gene ontology categories (Biological Process; Molecular
Signatures Database Perturbation) with associated top-ranked terms are shown for each cluster. Values on column plots represent –log10(binomial p-value),
computed using GREAT [35] (version 2.0.2) with the default association rules. Note: some ontology term names were shortened.
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those of H3K9ac [24]; signals for both activating marks
were reduced in genomic regions where AML1-ETO and
N-CoR were elevated (data not shown). HDAC activity
may decrease H3K9ac signals at these regions, a change
that may be achieved by direct interactions between
AML1-ETO and HDACs or via recruitment of HDACs
by N-CoR. Similarly, in transcription start site-proximal
regions, H3K4me3 enrichment may be reduced when
AML1-ETO/N-CoR occupancy is high.
Given that the fusion protein occupies Kasumi-1 meta-
phase chromosomes [20], it is possible that during mi-
tosis AML1-ETO associates with chromatin regulators
at novel genes that are critical for maintaining the
leukemic phenotype. This epigenetic gene bookmarking
mechanism has been described for Runx2 in osteoblastic
cells [33,48,49] and for PcG proteins in Drosophila S2
cells [50]. Future work on purified populations of mitotic
Kasumi-1 cells will shed light on whether AML1-ETO
participates in gene bookmarking.
Collectively, our data have revealed a global AML1-
ETO/N-CoR signature with two key properties: occu-
pancy of promoter-distal regions of AML1-ETO-regulated
genes, and enrichment for myeloid-related ETS factors.
Genes within this regulatory network define the disease
phenotype of t(8;21) leukemia and are potential thera-
peutic targets.
Conclusions
Findings presented here establish a novel t(8;21) AML
leukemia signature characterized by occupancy of AML1-
ETO/N-CoR at promoter-distal genomic regions enriched
in motifs for myeloid differentiation factors. These findings
are significant because a genome-wide mechanism for
AML1-ETO mediated block in myeloid differentiation re-
mains poorly understood. Results reported in this
study provide insight into genome-wide mechanisms
that contribute to the disease phenotype of the t(8;21)
carrying leukemia.
Methods
Cell lines and reagents
Kasumi-1 and K562 cell lines were purchased from the
American Type Culture Collection (ATCC, Manassas,
VA) and maintained in RPMI-1640 media supplemented
with 20% FBS. AML1 antibodies were purchased from
Cell Signaling Technology, Inc. (4334, Danvers, MA),
Abcam (50541, Cambridge, MA), EMD Millipore (PC285,
Billerica, MA), and Active Motif (39000, Carlsbad, CA).
The Cell Signaling Technology and Active Motif AML1
antibodies gave robust AML1 pulldowns and displayed
significant ChIP-PCR enrichments of control genomic
regions. The Cell Signaling Technology AML1 antibody
recognizes the N-terminal region of AML1, thus pull-
ing down both wildtype AML1 and AML1-ETO. In
contrast, the Active Motif AML1 antibody recognizes
the C-terminal region of AML1 and does not pull down
the AML1-ETO fusion protein. Therefore, the Active
Motif antibody was used for AML1 ChIP-seq library
preparations. An ETO antibody, PC283, was purchased
from EMD Millipore (Billerica, MA). N-CoR (SC-1609)
and p300 (SC-585) antibodies were purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). A
histone H3 (tri methyl K4) antibody (ab1012) was pur-
chased from Abcam (Cambridge, MA) and a histone
H3 (tri methyl K27) antibody (ABE44) was purchased
from EMD Millipore (Billerica, MA).
ChIP-seq library preparation
Kasumi-1 cells growing in log phase were fixed with 1%
formaldehyde for 10 min at room temperature and sub-
sequently quenched with 0.25 M glycine. After washes
in PBS, cells were flash frozen in liquid nitrogen. Thawed
pellets were resuspended in Buffer A (50 mM HEPES, 140
mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25%
Triton X-100) and rotated at 4°C for 10 min. Following
centrifugation, pellets were resuspended in Buffer B (10
mM Tris-HCl, 200 mM NaCl, 1 mM EDTA, 1 mM
EGTA) and rotated at 4°C for 10 min. Pellets from cen-
trifuged samples were resuspended in Buffer C (10 mM
Tris-HCl, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA,
0.1% sodium deoxycholate, 0.5% N-lauroylsarcosine).
Samples were aliquoted, 3 ml per tube, and sonicated
to a fragment size of 100-500 base pairs using a 3.2 mm
sonication probe (QSonica, Newtown, CT). Sheared
chromatin (from approximately 30 million cells) was
immunoprecipitated with antibodies overnight. All
ChIP experiments included either normal goat or rabbit
IgG (EMD Millipore, Billerica, MA) as controls.
Antibody-lysate complexes were mixed with Protein G
Dynabeads (Life Technologies, Grand Island, NY) for
two hours. For AML1, ETO, H3K4me3, and H3K27me3
immunoprecipitations, beads were washed once with IP
buffer, three times with RIPA buffer (50 mM HEPES, 500
mM LiCl, 1 mM EDTA, 0.5% NP-40, 0.25% sodium deox-
ycholate), once with PBS, and once with TE buffer. For N-
CoR and p300 pulldowns, beads were washed once with
IP buffer, once with high salt buffer (2 mM EDTA, 20 mM
Tris-HCl, 500 mM NaCl), 1 time with RIPA buffer (50
mM HEPES, 250 mM LiCl, 1 mM EDTA, 0.5% NP-40,
0.25% sodium deoxycholate), once with PBS, and once
with TE buffer. Protein-DNA complexes were extracted
from beads at 37°C in elution buffer (10 mM EDTA, 50
mM Tris-HCl, 1% SDS). For reverse crosslinking, superna-
tants from centrifuged samples were rotated overnight at
60°C. RNAse and proteinase K treated samples were
extracted with phenol:chloroform:isoamyl alcohol. Precipi-
tated DNA was resuspended in 10 mM Tris-HCl,
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quantified with a Qubit fluorometer (Life Technologies,
Grand Island, NY).
Prior to processing raw ChIP material for deep se-
quencing, ChIP-PCR validation studies were employed.
Positive and negative control binding regions were
established using different primers sets, and data was
expressed as percentage of input for each region. In
addition to site-specific enrichment for ChIP samples,
IgG was used as the non-specific control. A second
round of ChIP-PCR was performed following amplifica-
tion of libraries to ensure enrichment of genomic
regions in ChIP samples relative to input. Primer se-
quences used in ChIP-PCR studies (including ChIP-seq
target validation) can be found in Additional file 9:
Table S2.
The Illumina protocol (Illumina, Inc., San Diego, CA)
for ChIP-seq library generation was used with slight
modifications. Approximately 5-10 ng chromatin was
end-repaired (EpiCentre Biotechnologies, Madison, WI).
Material was then A-tailed and ligated with adapters for
single end deep sequencing (Illumina, Inc., San Diego,
CA). Adapter modified DNA was size-selected, 300-400
base pair (bp) range, and then amplified using the Phu-
sion polymerase (New England Biolabs, Ipswich, MA).
Amplified ChIP libraries were size selected and sequenced
on an Illumina GAIIx Genome Analyzer (Illumina, Inc.,
San Diego, CA) at the UMass Medical School Deep Se-
quencing Core Facility (Worcester, MA). Two biological
ChIP-seq replicates and inputs were collected for AML1,
AML1-ETO, p300, N-CoR, H3K4me3, and H3K27me3.
Analysis of sequencing data
As a preliminary step, the read quality from ChIP-seq
experiments was assessed using FastQC [51]. Reads
were aligned to the human genome (GRCh37, hg19)
using bowtie (version 0.12.8) [52], allowing up to two
mismatches. Peak calling was performed using MACS
(version 2.0.10.20131216) [34] with default settings and
a p < 10−20 threshold. For the remainder of this report,
replicates for each regulatory protein or histone modifi-
cation were pooled prior to peak calling and the result-
ing occupancy/enrichment profiles were normalized to
10 million reads. The overlaps between ChIP-seq peaks,
summarized in Figure 1, were based upon peak sum-
mits ± 50 bp. Using binding loci for AML1 and/or
AML1-ETO (peak summits ± 50 bp, with peaks merged
from the two pooled experiments), mean ChIP-seq read
densities were collected for a set of ChIP-seq experi-
ments and clustered by k-means (k = 3). In order to de-
termine an appropriate choice for k, we clustered our
signals, examined the sum of the squared error (SSE)
for 1 ≤ k ≤ 15 and compared this error with that from a
set of 250 randomized instances of the data [53]. We
observed that the difference between the actual SSE and
that for randomized data was maximal for k = 3.
De novo motifs were detected for each of the assayed
proteins (Figure 2C) using HOMER (v. 3.15) [54]. Dis-
tinguishing binding of specific transcription factors
within the ETS family is difficult because ETS factor mo-
tifs are similar. Therefore, our analysis makes a conser-
vative assignment by designating these motifs “ETS
family”. Candidate ETS transcription factors that relate
to t(8;21) leukemia are listed in the Discussion section.
To detect a de novo motif that can best distinguish be-
tween sequences from Cluster I and those in Clusters II
and III, we used the area under the receiver operating
curve (AUC) to compare candidate motifs [55] converging
from a random motif to an optimal one using a simulated
annealing procedure [56] with Metropolis-Hastings Monte
Carlo moves [57,58]. The resulting PU.1 de novo motif
(Additional file 8: Figure S7) was compared to known mo-
tifs using TOMTOM (version 4.9.1) [59] and was used
with FIMO [39] (version 4.7.0) with a significance thresh-
old of p < 10−4 to scan sequences in the clusters.
In order to evaluate the transcriptional effect of AML1-
ETO binding in association with N-CoR and p300, two
sets of previously reported gene expression profiling data
[24,30] were independently used in combination with our
clustered ChIP sequencing data. The first published ex-
pression data that we compared with [30] were collected
from Kasumi-1 cells that had been transfected with
AML1-ETO or luciferase siRNA constructs by either
Amaxa nucleofection or using Bio-Rad siLentFect. The
raw expression data were preprocessed and normalized
using GCRMA [60]. These Kasumi-1 microarrays were
originally processed in two batches on different dates and
the global expression patterns were strongly clustered by
batch. We were able to control for this effect using the
linear model “~0 + transfection + AML1-ETO”, where
the “transfection” factor correlates with the batch dates
and the “AML1-ETO” factor indexes knockdown (or not)
of the AML1-ETO mRNA. Replicates were treated as
blocking factors in the linear model using limma [61]
and empirical Bayes-moderated t tests were performed
(Figure 4A and B). The linear model was fitted only for
probe-sets that were annotated with Entrez gene IDs;
when there was more than one probe-set with the same
gene ID, only the probe-set with the largest interquar-
tile range was retained. A regulatory target gene can be
assigned to each AML1/AML1-ETO locus on the basis
of locus-TSS proximity. For each gene, however, there
may be many candidate regulatory loci. Therefore, an
additional assumption was made: regulation via an
AML1-ETO/N-CoR (i.e., Cluster I) locus is dominant.
If a gene is putatively regulated by loci from each of
Clusters I, II and III, the Cluster I locus is assumed to
be limiting in its control of expression and the gene is
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assigned exclusively to Cluster I for the purposes of
comparing aggregate changes in expression due to
binding for each of the clusters. A Fisher’s exact test
was used to measure associations between the Clusters
and genes regulated by AML1-ETO.
In order to reinforce the above analysis of transcrip-
tional outcomes associated with AML1-ETO/N-CoR co-
localization, we carried out steps similar to those outlined
above using another set of previously reported gene ex-
pression profiling data, collected in Kasumi-1 cells under
knockdown (or not) of the AML1-ETO mRNA [24].
These expression data were collected, without replication,
over a series of four time-points following electroporation
with either AML1-ETO siRNA or mismatch siRNA. Nor-
malized expression data were collected from the NCBI
Gene Expression Omnibus [62]. After retaining only
probe-sets that were annotated with Entrez gene IDs and,
when there was more than one probe-set with the same
gene ID, retaining only the probe-set with the largest
interquartile range, a linear model was fitted. We used
the linear model “~0 + time-point + AML1-ETO”. The
“time-point” variable enforces explicit pairing between
the AML1-ETO and mismatch siRNA conditions: the
resulting empirical Bayes-moderated t tests from limma
[61] are, therefore, paired t tests (Figure 4C and D).
Immunoprecipitation and western blotting
Kasumi-1 cells were centrifuged at 300 × g, resuspended
in PBS, and centrifuged again at 300 × g. Cells were
lysed in buffer (20 mM Tris, 0.15M NaCl, 1 mM EDTA,
1 mM EGTA, 1% Triton X-100, 1 mM PMSF), vortexed,
and kept on ice for 20 min. Samples were centrifuged at
10,000 × g for 10 min. Supernatants were collected and
protein concentration was determined by the BCA Assay
(Thermo Scientific, Rockford, IL). Whole cell Kasumi-1
extracts (500 μg) were immunoprecipitated overnight
with 2 μg of either p300 or N-CoR antibodies (Santa
Cruz Biotechnologies Inc., Santa Cruz, CA). Rabbit or
goat IgG were used as controls (Millipore, Billerica,
MA). Samples were rotated with 30 μl Protein G
Dynabeads (Life Technologies, Grand Island, NY) for
two hours, and then washed five times with IP buffer.
Protein samples were run on a 5% SDS-PAGE gel and
transferred to PVDF membranes (Thermo Scientific,
Rockford, IL). Membranes were blotted with p300 and
N-CoR antibodies (1:750 dilution) overnight. Second-
ary antibodies conjugated with HRP were purchased
from EMD Millipore (Billerica, MA). Enhanced chemi-
luminescence was used for protein detection (Thermo
Scientific, Rockford, IL).
Availability of supporting data
The data discussed in this publication have been de-
posited in NCBI’s Gene Expression Omnibus [62] and




aGenes exhibiting substantially altered expression are
defined here to have log2(fold-change) > 1 and p < 0.01.
Additional files
Additional file 1: Figure S1. Antibody validation prior to ChIP library
preparation. (A) ChIP-western experiments on crosslinked Kasumi-1
cells using a panel of AML1 antibodies and an AML1-ETO antibody. An
Active Motif AML1 antibody (39000, Carlsbad, CA) was used for ChIP-
seq library preparations. Blots were cropped for clarity. (B) Western blots
for p300 and N-CoR using Kasumi-1 and K562 whole cell lysates. (C)
Immunoprecipitation and western blot of N-CoR in Kasumi-1 cells
(using ChIP buffer C). IgG served as the control for all experiments.
Additional file 2: Figure S2. ChIP library validation in Kasumi-1 cells.
(A) ChIP-PCR experiments demonstrated significant pulldown of a
region in the Runx1P1 promoter in ChIP samples but not in IgG control
samples. Binding was negligible at the negative control hPhox region.
The strength of pulldowns are expressed as percent input. Experiments
were repeated twice and error bars represent standard deviation. (B)
Representative bioanalyzer results for AML1 and AML1-ETO libraries.
Each library displays a size-selected, narrow fragment range amenable
for deep sequencing.
Additional file 3: Table S1. ChIP-Seq library overview. Shown are the
number of reads and peaks called for each replicate ChIP-Seq library.
Additional file 4: Figure S3. Tag density plots and ChIP validaton of
AML1-ETO target genes. (A) Tag density plots displaying enriched
AML1-ETO regions corresponding to known fusion protein target genes.
Asterisks indicate the positions of TYROBP, LAPTM5, and RPS6KA1 regions
validated in ChIP-PCR studies (B). Fold enrichment indicates enrichment of
ChIP samples over inputs when equivalent amounts of DNA were used in
PCR reactions.
Additional file 5: Figure S4. Correlation between different ChIP-seq
libraries. Scatter plots for five ChIP-seq experiments collected using
Kasumi-1 cells. Each point represents a region of enrichment (i.e. “peak”) in
either the AML1, AML1-ETO or both experiments, with the normalized mean
read number, SX, plotted for five antibodies with target X on a logarithmic
scale. The lower triangle of the figure is comprised of scatter plots for pair-
wise comparisons, while the upper triangle reports the corresponding
correlation coefficients (Pearson’s r).
Additional file 6: Figure S5. Ontologies for genomic regions co-occupied
by AML1-ETO and co-regulatory proteins. (A-B) Gene ontology (GO) categories
(Biological Process; Molecular Signatures Database Perturbation) with
associated top-ranked terms are shown for genomic regions associated
with exclusive AML1-ETO/N-CoR enrichments (see 4252 overlapping
regions in Figure 1C) and AML1-ETO/p300 enrichments (see 1164
overlapping regions in Figure 1C). These genomic regions were defined
using the Venn diagram in Figure 1C and genomic coordinates were
associated with GO categories using GREAT [35] (version 2.0.2). Note
that no Biological Process terms were reported by GREAT (using the
default association rules) for AML1-ETO/p300. Ontology terms reflecting
regions of shared occupancy (see Figure 1C) between AML1-ETO/N-CoR/
p300 (C) and AML1/N-CoR/p300 (D) are also reported. Values on column
plots represent –log10(binomial p-value), computed using GREAT with the
default association rules. Note: some ontology term names were shortened.
Additional file 7: Figure S6. H3K27me3 ChIP-seq regions. Tag density
plots of H3K27me3 data (normalized to 107 reads) at CXCR4 and HCK loci.
Additional file 8: Figure S7. De novo discriminative motif. De novo
motif (see Methods for details) to distinguish Cluster I loci from those of
the other two clusters (see Figure 3A and D). Using TOMTOM (version
4.9.1) [59] to compare this motif with those from the TRANSFAC (Matys V
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et al., Nucleic Acids Res. 2006, 34(Database Issue):D108-10) and JASPAR
(Mathelier A et al., Nucleic Acids Res. 2014, 42(Database Issue):D142-47)
repositories, the TRANSFAC V_PU1_Q4 motif was the closest match,
followed by V_PU1_01 and the JASPAR motif MA0080.2 (SPI1, also
known as PU.1).
Additional file 9: Table S2. Oligonucleotides used in ChIP-PCR validation
studies.
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